Nirav Shah, MD, on New Data on Zamto-cel in DLBCL, Mantle Cell Lymphoma

“We're always trying to improve on the current standard of care. I think that right now CD19 is the current standard of care and a great option for patients. We've been looking at this dual targeting approach to see if we can improve upon that, and so I look forward to this trial data maturing for diffuse large B-cell lymphoma, and for mantle cell, right now it’s a single center study, but we think that these data justify a multicenter phase 2 study."

Zamtocabtagene autoleucel (zamto-cel; Miltenyi Biomedicine), a CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy, demonstrated safety and efficacy in updated data from a single center, phase 1/2 prospective trial (NCT04186520) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) as well as data from the multicenter, phase 2 DALY II USA trial (NCT04792489) in patients with R/R diffuse large B-cell lymphoma (DLBCL).

Nirav Shah, MD, associate professor of medicine, Medical College of Wisconsin, presented the data in 2 presentations at the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held February 15-18 in Orlando, Florida. CGTLive spoke with Shah to learn more about zamto-cel and the advantages and research being conducted with dual-targeting CAR T therapies. He outlined the data presented and highlighted the favorable safety profile of the therapy.

Click here for more coverage of the 2023 Tandem Meetings.

REFERENCES

1. Shah NN, Furqan F, Szabo A, et al. Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma. Presented at: 2023 Tandem Meetings. Abstract #40
2. Shah NN, Maziarz RT, Ghosh M, et al. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy - Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/Refractory (R/R) DLBCL (DALY II USA NCT04792489). Presented at: 2023 Tandem Meetings. Abstract #16